Evidence map›Paper›PMID 34426673›Full record

ReviewNature reviews. Cardiology2022

Bleeding avoidance strategies in percutaneous coronary intervention.

Davide Capodanno, Deepak L Bhatt, C Michael Gibson, Stefan James, Takeshi Kimura, Roxana Mehran, Sunil V Rao, Philippe Gabriel Steg, Philip Urban, Marco Valgimigli and 2 more

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 61 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05024864 naactive not recruitingnot on this map

HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction (HELP-MI SWEDEHEART)

TypeinterventionalSponsorKarolinska InstitutetRan2021 to 2030Enrolled20,000ConditionsMyocardial Infarction, Helicobacter Pylori Infection, GastroIntestinal Bleeding, Cardiovascular DiseasesArmsUrea breath test (UBT)
NCT05681702 phase4recruitingnot on this mapstarted 2023, after this paper: background citation

Tailoring Bleeding Reduction Approaches in Patients Undergoing Percutaneous Coronary Interventions: Comparative Pharmacodynamic Effects of Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy De-escalation

TypeinterventionalSponsorUniversity of FloridaRan2023 to 2027Enrolled90ConditionsCoronary Artery DiseaseArmsaspirin plus clopidogrel, prasugrel or ticagrelor
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. P2YJournal of the American Heart Association · 2025
    Pooled it
  4. Pooled it
  5. Trial
  6. Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Trial
  7. Trial
  8. Trial
  9. Review
  10. Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. The Negative Influence and Adverse Outcome of Red Blood Cell Transfusion in Contemporary Percutaneous Coronary Interventions.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Davide CapodannoDivision of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy.
Deepak L BhattDepartment of Medicine, Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1278-6245
C Michael GibsonDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4857-9125
Stefan JamesDepartment of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-4413-9736
Takeshi KimuraDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Roxana MehranCardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-5546-262X
Sunil V RaoThe Duke Clinical Research Institute, Durham, NC, USA.
Philippe Gabriel StegDépartement Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Paris, France.
Philip UrbanHôpital de la Tour, Geneva, Switzerland.
Marco ValgimigliCardiocentro Ticino Institute and Università della Svizzera italiana (USI), Lugano, Switzerland.
Stephan WindeckerDepartment of Cardiology, Bern University Hospital, Bern, Switzerland.
Dominick J AngiolilloUniversity of Florida College of Medicine, Jacksonville, FL, USA. dominick.angiolillo@jax.ufl.edu.ORCID http://orcid.org/0000-0001-8451-2131

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For many years, bleeding has been perceived as an unavoidable consequence of strategies aimed at reducing thrombotic complications in patients undergoing percutaneous coronary intervention (PCI). However, the paradigm has now shifted towards bleeding being recognized as a prognostically unfavourable event to the same extent as having a new or recurrent ischaemic or thrombotic complication. As such, in parallel with progress in device and drug development for PCI, there is clinical interest in developing strategies that maximize not only the efficacy but also the safety (for example, by minimizing bleeding) of any antithrombotic treatment or procedural aspect before, during or after PCI. In this Review, we discuss contemporary data and aspects of bleeding avoidance strategies in PCI, including risk stratification, timing of revascularization, pretreatment with antiplatelet agents, selection of vascular access, choice of coronary stents and antithrombotic treatment regimens.

Indexed as

Percutaneous Coronary InterventionAnticoagulantsHemorrhageHumansPlatelet Aggregation InhibitorsStentsTreatment OutcomeAnticoagulantsPlatelet Aggregation Inhibitors

Identifiers

PMID34426673

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.